Therapeutic window study. Saline and DHA (5 mg/kg) were administered at 3h, Albumin (1.25 g/kg) at 3 h or 5 h and DHA-Albumin (5 mg/kg + 1.25 g/kg) at 2, 3, 4, 5, 6 or 7 h after onset of MCAo. (A) Total neurological score in Alb, DHA and DHA-Alb (at 2, 3 and 4h) and (B) Alb, DHA-Alb (at 5, 6 and 7 h) treated groups. Total, cortical and subcortical infarct volumes in (C) Alb, DHA and DHA-Alb (at 2, 3 and 4 h) and (D) Alb, DHA-Alb (at 5, 6 and 7 h) treated groups. DHA-Alb therapy led to significantly improved neurological score and highly significant reductions of total, cortical and subcortical infarct volumes, even when treatment was initiated as late as 7 h after onset of MCAo. Data are mean ±SEM; n=7-9 per group. *P <0.05 versus saline group; #
P <0.05 versus Alb group (repeated-measures ANOVA followed by Bonferroni tests).